To prepare the Eriodictyol chewable tablet and to evaluate its quality.
METHODS
2
The chewable tablet was prepared by the wetting granulation method by using microcrystalline cellulose (MCC) and mannitol as fillers, polyvinylpyrrolidone (PVP) as adhesive, citric acid and sucralose as flavor correction agents, magnesium stearate as lubricant. The comprehensive evaluation was conducted on Eriodictyol chewable tablets with the dosage of each excipient as a factor using the appearance, taste, flavor and texture as indicators. The ratio of excipients was optimized by orthogonal test, and the quality of Eriodictyol chewable tablets prepared by optimized formulation was evaluated in terms of appearance, weight difference, hardness, fragility, eriodictyol content, dissolution and content uniformity.
RESULTS
2
The optimal formulation was as follows: 26.4% eriodictyol (50 mg each piece), 45% mannitol, 25% MCC, 0.3% citric acid, 0.3% sucralose, 1% magnesium stearate, 2% PVP (preparing 5% solution using purified water). The scores of 3 batches of Eriodictyol chewable tablets in the validation test were 8.76, 8.75 and 8.80 (RSD=0.30%,
n
=3), respectively. The Eriodictyol chewable tablet had a complete appearance and a smooth surface; the average tablet weight was 192.57 mg, the average hardness was 57.36 N, the fragility was 0.09%, the average content of eriodictyol per tablet was 50.74 mg, the cumulative dissolution within 30 min was ex
ceeding 80%, and the content uniformity was 5.51.
CONCLUSIONS
2
Eriodictyol chewable tablet prepared by optimal formulation conforms to the requirements of the 2020 edition of
Chinese Pharmacopoeia
.
关键词
Keywords
references
GUO S , XING N , XIANG G L , et al . Eriodictyol:a review of its pharmacological activities and molecular mechanisms related to ischemic stroke [J ] . Food Funct , 2023 , 14 ( 4 ): 1581 - 1868 .
LI W J , DU Q , LI X L , et al . Eriodictyol inhibits proliferation,metastasis and induces apoptosis of glioma cells via PI3K/Akt/NF-κB signaling pathway [J ] . Front Pharmacol , 2020 , 11 : 114 .
LI L , LI W J , ZHENG X R , et al . Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation [J ] . Mol Med , 2022 , 28 ( 1 ): 11 .
XIE G H , MENG X L , WANG F , et al . Eriodictyol attenuates arsenic trioxide-induced liver injury by activation of Nrf2 [J ] . Oncotarget , 2017 , 8 ( 40 ): 68668 - 68674 .
ZHU C M , TENG J H , ZHANG M , et al . Research pro-gress on quality evaluation methods of chewable tablets [J ] . Chin J N Drugs , 2022 , 31 ( 7 ): 645 - 654 .
ZHANG L . Preparation of compound Dangshen superfine powder chewable tablets [J ] . J Shanxi Univ Chin Med , 2020 , 21 ( 5 ): 345 - 348 .
RIBEIRO C B , RAMOS F M , MANTHEY J A , et al . Effectiveness of Eriomin ® in managing hyperglycemia and reversal of prediabetes condition:a double-blind,rando-mized,controlled study [J ] . Phytother Res , 2019 , 33 ( 7 ): 1921 - 1933 .
LI H J , WANG Y F , CHU W J , et al . Scale inhibition performance evaluation and mechanism of carboxymethyl chitosan [J ] . Appl Chem Ind , 2020 , 49 ( 5 ): 1101 - 1104 .
National Pharmacopoeia Commission . Pharmacopoeia of the People’s Republic of China:part Ⅳ [M ] . 2020 edition. Beijing : China Medical Science and Technology Press , 2020 : 131 - 137 .